Clin2
NCT07125950Possibly a fitNot yet recruiting

SHR2554 plus hormone therapy for advanced breast cancer

Advanced Breast Cancer

Treatments studied

Part of Cancer, Hormones & metabolism clinical trials.

This trial tests a new drug, SHR2554, combined with hormone therapy for people with advanced or metastatic breast cancer. It aims to see if the combination can help control the cancer when standard treatments are no longer working.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • Your breast cancer has spread to other parts of the body (advanced or metastatic).
  • You are able to take care of yourself and are up and about (ECOG score 0 or 1).
  • You have at least one tumor that can be measured on scans.
  • Your organs (like liver, kidneys, blood) are working well enough.
  • If you could become pregnant, you agree to use effective birth control during the study and for 7 months after the last dose.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07041437Not yet recruiting· Phase 2
SHR-A2102 plus other drugs for advanced breast cancer

This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.

Shanghai, Shanghai Municipality
NCT06470672Not yet recruiting· Phase 2
Study of SHR-A1921 plus Adebrelimab for advanced breast cancer

This trial tests a combination of two drugs—SHR-A1921 (a targeted therapy) and Adebrelimab (an immunotherapy)—for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, PD-L1 positive). It aims to see if this combo can help when hormone therapy and chemotherapy haven't worked well enough.

Shanghai, Shanghai Municipality
NCT06433609Recruiting· Phase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer

This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.

Beijing, Beijing Municipality
NCT06955390Not yet recruiting· Phase 1/Phase 2
Testing a drug combo for advanced solid tumors

This trial tests two drugs, HRS-4642 and SHR-A2102, for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if this combination can help shrink or slow tumor growth.

Zhengzhou, Henan
NCT06222879Recruiting· Phase 1/Phase 2
New drug combinations for advanced breast cancer

This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.

Changsha, Hunan
NCT06704828Not yet recruiting· Phase 2
SHR-4602 alone or with other therapies for advanced solid tumors

This trial tests a new drug called SHR-4602, alone or with other cancer treatments, for people with advanced solid tumors that have HER2 protein. It may be an option if you have already tried standard therapies and your cancer is still growing.

Beijing, Beijing Municipality

Hear when a new Advanced Breast Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.